Clinical trials: Unresectable Gastrointestinal Stromal Tumor (GIST), open to volunteers
Gastrointestinal Stromal Tumors
Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments
To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies
- Trial name
- NCT07618377
- Testing
- DCC-2618
- Where
- 2 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Gastrointestinal Stromal Tumors
Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
The goal of this prospective study is to learn whether there is a synergistic effect when radiotherapy is combined with ripretinib in the treatment of patients with unresectable advanced GIST.
- Trial name
- NCT06507683
- Testing
- simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Gastrointestinal Stromal Tumors, Unresectable Solid Tumor
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
This is a prospective, multicenter, observational real-world study to explore the therapy patterns and clinical outcomes of Avapritinib in patients with metastatic or unresectable gastrointestinal stromal tumors.
- Conditions
- Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
- Trial name
- NCT05464875
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Xinhua Zhang, MD
Gastrointestinal Stromal Neoplasms
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine.
- Trial name
- NCT07585266
- Testing
- Velzatinib, Imatinib
- Where
- 93 sites in United States, Argentina and 18 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Neoplasms
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who…
- Trial name
- NCT07689201
- Testing
- Velzatinib
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients.
- Trial name
- NCT05208047
- Testing
- CGT9486, Sunitinib, Midazolam
- Where
- 126 sites in United States, Argentina and 20 more
- Volunteers
- 482 people
- Sponsor
- Cogent Biosciences, Inc.
Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor
Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors
This phase II trial tests the effect of autologous tumor infiltrating lymphocytes (TILs) in combination with interleukin-2 (aldesleukin) in treating patients with gastrointestinal stromal tumors (GIST) that has spread to nearby…
- Conditions
- Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor, Recurrent Gastrointestinal Stromal Tumor, Refractory Malignant Gastrointestinal Stromal Tumor
- Trial name
- NCT07647068
- Testing
- Aldesleukin, Biospecimen Collection, Chest Radiography
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Joal Beane
Gastrointestinal Stromal Tumors, Unresectable Solid Tumor
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
This is a prospective, multicenter, observational real-world study to explore the Avapritinib therapy in GIST patients who definited Non-exon18 Mutations of PDGFRA.
- Conditions
- Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
- Trial name
- NCT05461664
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Xinhua Zhang, MD
Gastrointestinal Neoplasms
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug…
- Trial name
- NCT07218926
- Testing
- IDRX-42, Sunitinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline